{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:56:44Z","timestamp":1793120204273,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T00:00:00Z","timestamp":1665792000000},"content-version":"am","delay-in-days":409,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.therap.2020.09.003","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T07:27:41Z","timestamp":1601018861000},"page":"449-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["TNF-\u03b1 inhibitors and psychiatric adverse drug reactions in the spectrum of bipolar (manic) or psychotic disorders: Analysis from the French pharmacovigilance database"],"prefix":"10.1016","volume":"76","author":[{"given":"C\u00e9cile Marie","family":"Yelnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Gaboriau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Petitpain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Th\u00e9ophile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Delaporte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Carton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2020.09.003_bib0110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00004850-200507000-00008","article-title":"Etanercept, anticytokines and mania","volume":"20","author":"Kaufman","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2020.09.003_bib0115","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/rheumatology\/ken212","article-title":"Acute psychosis in three patients receiving anti-tumour necrosis factor-alpha therapy","volume":"47","author":"McGregor","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.therap.2020.09.003_bib0120","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1440-1819.2010.02096.x","article-title":"Induction of manic switch by the tumour necrosis factor-alpha antagonist infliximab","volume":"64","author":"Elisa","year":"2010","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.therap.2020.09.003_bib0125","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/0004867412450473","article-title":"Mania associated with infliximab","volume":"46","author":"Austin","year":"2012","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.therap.2020.09.003_bib0130","first-page":"2014","article-title":"Schizophrenia-like disorder associated with etanercept treatment","volume":"13","author":"Atigari","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.therap.2020.09.003_bib0135","article-title":"Acute psychosis in an adolescent treated with infliximab for Crohn's disease","volume":"17","author":"Locher","year":"2015","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.therap.2020.09.003_bib0140","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.therap.2019.09.004","article-title":"Pharmacovigilance: the next chapter","volume":"74","author":"Moore","year":"2019","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2020.09.003_bib0145","first-page":"111","article-title":"Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France","volume":"40","author":"B\u00e9gaud","year":"1985","journal-title":"Th\u00e9rapie"},{"key":"10.1016\/j.therap.2020.09.003_bib0150","unstructured":"Prescrire. Fiche E19e\u2013Troubles psychotiques m\u00e9dicamenteux en bref. February 2019. http:\/\/www.prescrire.org.[Accessed August 27, 2020]."},{"key":"10.1016\/j.therap.2020.09.003_bib0155","unstructured":"Prescrire. Fiche E19h\u2013Episodes maniaques m\u00e9dicamenteux en bref. February 2019. http:\/\/www.prescrire.org. [Accessed August 27, 2020]."},{"issue":"359","key":"10.1016\/j.therap.2020.09.003_bib0160","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"4","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"350","key":"10.1016\/j.therap.2020.09.003_bib0165","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"26","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"issue":"353","key":"10.1016\/j.therap.2020.09.003_bib0170","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"8","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2020.09.003_bib0175","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gut.2008.163642","article-title":"Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study","volume":"58","author":"Fidder","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.therap.2020.09.003_bib0180","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1111\/j.1572-0241.2000.03366.x","article-title":"Clinical experience with infliximab therapy in 100 patients with Crohn's disease","volume":"95","author":"Farrell","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.therap.2020.09.003_bib0185","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.schres.2009.01.018","article-title":"Successful treatment of psychosis with infliximab in a patient with Crohn's disease","volume":"109","author":"Reimer","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.therap.2020.09.003_bib0190","doi-asserted-by":"crossref","first-page":"734","DOI":"10.4088\/JCP.v64n0618e","article-title":"Improvement in negative symptoms of schizophrenia with antibodies to tumor necrosis factor-alpha and to interferon-gamma: a case report","volume":"64","author":"Skurkovich","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.therap.2020.09.003_bib0195","first-page":"1046","article-title":"Exacerbation of paranoid schizophrenia in a psoriatic patient after treatment with cyclosporine A, but not with etanercept","volume":"6","author":"Di Nuzzo","year":"2007","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"10.1016\/j.therap.2020.09.003_bib0200","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2165\/11537780-000000000-00000","article-title":"Comparison of three methods (consensual expert judgement, algorithmic and probabilistic approaches) of causality assessment of adverse drug reactions: an assessment using reports made to a French pharmacovigilance centre","volume":"33","author":"Th\u00e9ophile","year":"2010","journal-title":"Drug Safety"},{"key":"10.1016\/j.therap.2020.09.003_bib0205","doi-asserted-by":"crossref","first-page":"558","DOI":"10.2174\/1570159X13666150630171433","article-title":"The involvement of TNF-\u03b1 in cognitive dysfunction associated with major depressive disorder: an opportunity for domain specific treatments","volume":"13","author":"Bortolato","year":"2015","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.therap.2020.09.003_bib0210","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s002280050498","article-title":"Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system","volume":"54","author":"Alvarez-Requejo","year":"1998","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720301529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720301529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:12Z","timestamp":1758567252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720301529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0040595720301529"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.09.003","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TNF-\u03b1 inhibitors and psychiatric adverse drug reactions in the spectrum of bipolar (manic) or psychotic disorders: Analysis from the French pharmacovigilance database","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}